Desk›Healthcare› Neuland Laboratories Ltd
Neuland Laboratories Ltd
BSE 524558 · NSE NEULANDLAB · ISIN INE794A01010 · Group A · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹23,492.85
-0.27%
BSE close, 28 August 2026
₹30,141.07 cr
1.3 cr shares · Mid cap
₹20,165.37 cr
as published
60.7× · 21.71×
EPS ₹387.19 · BV ₹1,082.12
2,022.99 / 363.11
₹ cr, as filed
25
7 selected · 28%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -1.7% |
|---|---|
| Against 52-week low | +104.3% |
| Day change | -0.27% |
| Size band | Mid cap |
| Index membership | NIFTY 500 |
Valuation as published by BSE
| Earnings per share | ₹387.19 |
|---|---|
| Price / earnings | 60.68× |
| Price / book | 21.71× |
| Book value — derived, price ÷ P/B | ₹1,082.12 |
| Return on equity | 35.78% |
| Operating margin | 36.02% |
| Net margin | 22.97% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 35.78%
- ROE as published
- 35.78%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 641.58 | 147.36 | 114.86 | 36.02% | 22.97% |
| Mar-26 · Q | 776.25 | 212.52 | 165.65 | 41.14% | 27.38% |
| FY25-26 | 2,022.99 | 363.11 | 283.01 | 29.83% | 17.95% |
Quarter on quarter
- Revenue, quarter on quarter
- -17.3%
- Net profit, quarter on quarter
- -30.7%
- Operating margin, quarter on quarter
- -512 bps
Disclosure profile 25 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Press Release | 2 |
| Board Outcome | 1 |
| Concall Transcript | 1 |
| Credit Rating | 1 |
| Investor Presentation | 1 |
| Results | 1 |
| Selected sub-total | 7 |
| Procedural | |
| Analyst / Investor Meet | 5 |
| General | 5 |
| AGM / EGM | 2 |
| Board Meeting | 1 |
| Compliance Certificate | 1 |
| Duplicate Certificate | 1 |
| Newspaper Publication | 1 |
| SAST | 1 |
| Trading Window | 1 |
| Procedural sub-total | 18 |
| Total | 25 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
25 filings · 7 selected · busiest 2026-08-05
Filing rhythm · the twelve most recent
2026-08-062026-10-05
SelectedProcedural
Filings
25 in the window · 11 earlier on record
-
5 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
25 September 2026 ·
Closure of Trading Window
Closure of Trading Window
Insider Trading / SAST / Closure of Trading Window View filing →
-
16 September 2026 ·
Analyst / Investor Meet - Intimation
Intimation about Schedule of Analyst / Institutional Investor Meeting on September 23 - 25, 2026
Company Update / Analyst / Investor Meet View filing →
-
15 September 2026 ·
Press Release / Media Release
Press Release
Company Update / Press Release / Media Release View filing →
-
9 September 2026 ·
Analyst / Investor Meet - Intimation
Intimation about Schedule of Analyst / Institutional Investor Meeting on September 15, 2026 and September 17, 2026
Company Update / Analyst / Investor Meet View filing →
-
7 September 2026 ·
Disclosure Under Regulation 30 Of SEBI Listing Regulations
Disclosure under Regulation 30 of SEBI Listing Regulations
Company Update / General View filing →
-
25 August 2026 ·
Credit Rating
Announcement under Regulation 30 (LODR) - Credit Rating
Company Update / Credit Rating View filing →
-
17 August 2026 ·
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Malabar India Fund Ltd
Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →
-
14 August 2026 ·
Intimation Regarding Completion Of US FDA Inspection
Intimation regarding completion of US FDA Inspection
Company Update / General View filing →
-
10 August 2026 ·
Earnings Call Transcript
Transcript of the Earnings Call conducted on August 5, 2026
Company Update / Earnings Call Transcript View filing →
-
7 August 2026 ·
Analyst / Investor Meet - Intimation
Intimation about Schedule of Analyst / Institutional Investor Meeting on August 12, 2026
Company Update / Analyst / Investor Meet View filing →
-
6 August 2026 ·
Newspaper Publication
Copy of Newspaper Publication
Company Update / Newspaper Publication View filing →
-
5 August 2026 ·
Analyst / Investor Meet - Outcome
Audio Recording of the Earnings call conducted on August 5, 2026
Company Update / Analyst / Investor Meet View filing →
-
5 August 2026 ·
Disclosure Under Regulation 30 Of SEBI Listing Regulations
Disclosure under Regulation 30 of SEBI Listing Regulations - Enhancement of manufacturing capacity
Company Update / General View filing →
-
5 August 2026 ·
Disclosure Under Regulation 30 Of SEBI Listing Regulations
Disclosure under Regulation 30 of SEBI Listing Regulations - Execution of deed of Corporate Guarantee
Company Update / General View filing →
-
5 August 2026 ·
Investor Presentation
Investor Presentation on the Financial Results of the Company for the quarter ended June 30, 2026
Company Update / Investor Presentation View filing →
-
5 August 2026 ·
Press Release / Media Release
Press Release on the Financial Results of the Company for the quarter ended June 30, 2026
Company Update / Press Release / Media Release View filing →
-
5 August 2026 ·
Unaudited Financial Results Of The Company For The Quarter Ended June 30, 2026
Unaudited Financial Results of the Company for the quarter ended June 30, 2026
Result / Financial Results View filing →
-
5 August 2026 ·
Board Meeting Outcome for Unaudited Financial Results Of The Company For The Quarter Ended June 30, 2026
Unaudited Financial Results of the Company for the quarter ended June 30, 2026
Board Meeting / Outcome of Board Meeting View filing →
-
4 August 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Voting Results, Scrutinizer Report and proceedings of 42nd Annual General Meeting held on August 4, 2026
AGM/EGM / AGM View filing →
-
4 August 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Voting Results, Scrutinizer Report and proceeding of 42nd Annual General Meeting held on August 4, 2026
AGM/EGM / AGM View filing →
-
31 July 2026 ·
Intimation Under Regulation 30 Of SEBI Listing Regulations
Intimation under Regulation 30 of SEBI Listing Regulations
Company Update / General View filing →
-
28 July 2026 ·
Analyst / Investor Meet - Intimation
Q1FY27 Earnings Call Intimation
Company Update / Analyst / Investor Meet View filing →
-
20 July 2026 ·
Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter Ended June 30, 2026
Neuland Laboratories Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve the unaudited financial ....
Board Meeting / Board Meeting View filing →
-
20 July 2026 ·
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificate(s)
Others / Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate View filing →
RSS feed for Neuland Laboratories Ltd · the 50 most recent filings